Anupam Rama
Stock Analyst at JP Morgan
(4.53)
# 288
Out of 5,182 analysts
309
Total ratings
52.06%
Success rate
23.65%
Average return
Main Sectors:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRAX First Tracks Biotherapeutics | Initiates: Overweight | $31 | $18.16 | +70.70% | 1 | Apr 23, 2026 | |
| REPL Replimune Group | Downgrades: Underweight | n/a | $2.42 | - | 13 | Apr 13, 2026 | |
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | $37 → $41 | $40.94 | +0.15% | 20 | Apr 1, 2026 | |
| MAZE Maze Therapeutics | Maintains: Overweight | $52 → $58 | $25.81 | +124.72% | 3 | Mar 31, 2026 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $44 → $41 | $40.50 | +1.23% | 5 | Mar 25, 2026 | |
| SLDB Solid Biosciences | Maintains: Overweight | $11 → $12 | $7.92 | +51.52% | 10 | Mar 25, 2026 | |
| ZLAB Zai Lab | Maintains: Overweight | $39 → $32 | $22.77 | +40.54% | 14 | Mar 18, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Overweight | $55 → $58 | $15.53 | +273.47% | 7 | Mar 18, 2026 | |
| ERAS Erasca | Maintains: Overweight | $24 → $25 | $21.49 | +16.33% | 2 | Mar 18, 2026 | |
| CTMX CytomX Therapeutics | Upgrades: Overweight | $7 → $12 | $4.40 | +172.73% | 4 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $176 → $177 | $127.68 | +38.63% | 22 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $74 | $24.10 | +207.05% | 4 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $89 → $94 | $73.28 | +28.28% | 13 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $45 | $21.39 | +110.38% | 12 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $11.05 | +189.59% | 1 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $99 → $96 | $37.69 | +154.71% | 12 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $67 | $36.81 | +82.02% | 9 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $40 | $13.81 | +189.65% | 2 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $147 → $145 | $104.50 | +38.76% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $7 → $6 | $8.22 | -27.01% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $20 | $10.24 | +95.31% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $13.31 | +27.72% | 1 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $14.49 | +31.12% | 14 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $44.84 | -46.48% | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $30.73 | +157.08% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.44 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $20.30 | +18.23% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $58.88 | +35.87% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $42.79 | -6.52% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.94 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.63 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.88 | +121.09% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $5.01 | +4,890.02% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.84 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $65.32 | -11.21% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $16.46 | -27.10% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $10.37 | +256.80% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $100.00 | -45.00% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 → $38 | $10.25 | +270.73% | 13 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $25.32 | +113.27% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $2,250 | $4.87 | +46,101.23% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $18.26 | +47.86% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $305.54 | -55.16% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $8.11 | +491.86% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $1.48 | +1,927.03% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $68.23 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.93 | - | 2 | Jul 21, 2017 |
First Tracks Biotherapeutics
Apr 23, 2026
Initiates: Overweight
Price Target: $31
Current: $18.16
Upside: +70.70%
Replimune Group
Apr 13, 2026
Downgrades: Underweight
Price Target: n/a
Current: $2.42
Upside: -
Apellis Pharmaceuticals
Apr 1, 2026
Downgrades: Neutral
Price Target: $37 → $41
Current: $40.94
Upside: +0.15%
Maze Therapeutics
Mar 31, 2026
Maintains: Overweight
Price Target: $52 → $58
Current: $25.81
Upside: +124.72%
Travere Therapeutics
Mar 25, 2026
Maintains: Overweight
Price Target: $44 → $41
Current: $40.50
Upside: +1.23%
Solid Biosciences
Mar 25, 2026
Maintains: Overweight
Price Target: $11 → $12
Current: $7.92
Upside: +51.52%
Zai Lab
Mar 18, 2026
Maintains: Overweight
Price Target: $39 → $32
Current: $22.77
Upside: +40.54%
Olema Pharmaceuticals
Mar 18, 2026
Maintains: Overweight
Price Target: $55 → $58
Current: $15.53
Upside: +273.47%
Erasca
Mar 18, 2026
Maintains: Overweight
Price Target: $24 → $25
Current: $21.49
Upside: +16.33%
CytomX Therapeutics
Mar 16, 2026
Upgrades: Overweight
Price Target: $7 → $12
Current: $4.40
Upside: +172.73%
Mar 12, 2026
Maintains: Overweight
Price Target: $176 → $177
Current: $127.68
Upside: +38.63%
Mar 12, 2026
Maintains: Overweight
Price Target: $120 → $74
Current: $24.10
Upside: +207.05%
Mar 10, 2026
Maintains: Overweight
Price Target: $89 → $94
Current: $73.28
Upside: +28.28%
Mar 9, 2026
Maintains: Overweight
Price Target: $33 → $45
Current: $21.39
Upside: +110.38%
Mar 3, 2026
Initiates: Overweight
Price Target: $32
Current: $11.05
Upside: +189.59%
Dec 19, 2025
Maintains: Overweight
Price Target: $99 → $96
Current: $37.69
Upside: +154.71%
Dec 19, 2025
Maintains: Overweight
Price Target: $65 → $67
Current: $36.81
Upside: +82.02%
Dec 19, 2025
Maintains: Overweight
Price Target: $43 → $40
Current: $13.81
Upside: +189.65%
Dec 19, 2025
Maintains: Overweight
Price Target: $147 → $145
Current: $104.50
Upside: +38.76%
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $8.22
Upside: -27.01%
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $10.24
Upside: +95.31%
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $13.31
Upside: +27.72%
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $14.49
Upside: +31.12%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $44.84
Upside: -46.48%
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $30.73
Upside: +157.08%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.44
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $20.30
Upside: +18.23%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $58.88
Upside: +35.87%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $42.79
Upside: -6.52%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $1.94
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.63
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.88
Upside: +121.09%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $5.01
Upside: +4,890.02%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.84
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $65.32
Upside: -11.21%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $16.46
Upside: -27.10%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $10.37
Upside: +256.80%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $100.00
Upside: -45.00%
Oct 11, 2021
Upgrades: Neutral
Price Target: $14 → $38
Current: $10.25
Upside: +270.73%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $25.32
Upside: +113.27%
Jan 11, 2021
Initiates: Overweight
Price Target: $2,250
Current: $4.87
Upside: +46,101.23%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $18.26
Upside: +47.86%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $305.54
Upside: -55.16%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $8.11
Upside: +491.86%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $1.48
Upside: +1,927.03%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $68.23
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.93
Upside: -